On April 12, GLONGHUI | Conoa-B (02162.HK) released an update on the licensing agreement between KYM Biosciences Inc. (“KYM”, a 70% non-wholly-owned subsidiary of the Group) and AstraZeneca AB (“AstraZeneca”, a global biopharmaceutical company) for the company's pipeline product CMG901 (AZD0901). In February 2023, KYM signed an exclusive global license agreement with AstraZeneca to develop and commercialize CMG901, which is the main product jointly developed by the Group and InnoCube Limited (controlled by Lepu Biotech Co., Ltd., a minority shareholder with 30% interest in KYM). After signing the license agreement and obtaining certain regulatory approvals in connection with the licensing transaction, AstraZeneca was granted an exclusive global license to research, develop, register, produce and commercialize CMG901 in February 2023, and is responsible for all costs and activities associated with its further development and commercialization in accordance with the license agreement.

As of the date of this announcement, AstraZeneca has conducted a number of clinical studies on CMG901 (AZD0901) in the treatment of advanced solid tumors. An international multicenter phase III study comparing AZD0901 monotherapy with the researchers' selected regimen as second-line or higher-line treatment in subjects with advanced or metastatic gastric and gastroesophageal adenocarcinoma expressing Claudin 18.2 was announced on the drug clinical trial registration and information platform in March 2024. The first test subjects completed their first dose on April 11, 2024.